Artificially Engineered Antiferromagnetic Nanoprobes for Ultra-sensitive Histopathological Level Magnetic Resonance Imaging
Overview
Authors
Affiliations
Histopathological level imaging in a non-invasive manner is important for clinical diagnosis, which has been a tremendous challenge for current imaging modalities. Recent development of ultra-high-field (UHF) magnetic resonance imaging (MRI) represents a large step toward this goal. Nevertheless, there is a lack of proper contrast agents that can provide superior imaging sensitivity at UHF for disease detection, because conventional contrast agents generally induce T2 decaying effects that are too strong and thus limit the imaging performance. Herein, by rationally engineering the size, spin alignment, and magnetic moment of the nanoparticles, we develop an UHF MRI-tailored ultra-sensitive antiferromagnetic nanoparticle probe (AFNP), which possesses exceptionally small magnetisation to minimize T2 decaying effect. Under the applied magnetic field of 9 T with mice dedicated hardware, the nanoprobe exhibits the ultralow r/r value (~1.93), enabling the sensitive detection of microscopic primary tumours (<0.60 mm) and micrometastases (down to 0.20 mm) in mice. The sensitivity and accuracy of AFNP-enhanced UHF MRI are comparable to those of the histopathological examination, enabling the development of non-invasive visualization of previously undetectable biological entities critical to medical diagnosis and therapy.
Wang K, Zhang S, Wang Y, Wu X, Wen L, Meng T J Neuroinflammation. 2024; 21(1):307.
PMID: 39609821 PMC: 11603931. DOI: 10.1186/s12974-024-03300-7.
Responsive probes for in vivo magnetic resonance imaging of nitric oxide.
Lu C, Liao S, Chen B, Xu L, Wu N, Lu D Nat Mater. 2024; 24(1):133-142.
PMID: 39587281 DOI: 10.1038/s41563-024-02054-0.
Counting cells in motion by quantitative real-time magnetic particle imaging.
Remmo A, Kosch O, Kampen L, Ludwig A, Wiekhorst F, Lowa N Sci Rep. 2024; 14(1):4253.
PMID: 38378785 PMC: 10879211. DOI: 10.1038/s41598-024-54784-5.
Stimuli-responsive crosslinked nanomedicine for cancer treatment.
Xue X, Qu H, Li Y Exploration (Beijing). 2023; 2(6):20210134.
PMID: 37324805 PMC: 10190936. DOI: 10.1002/EXP.20210134.
Zhang Y, Liu L, Li W, Zhang C, Song T, Wang P J Nanobiotechnology. 2023; 21(1):9.
PMID: 36609374 PMC: 9824934. DOI: 10.1186/s12951-023-01769-7.